Skip to main content
. 2019 Jun 22;91:5–9. doi: 10.1016/j.curtheres.2019.06.001

Table 3.

Vaccine development for schistosomiasis.

Agent Description Stage Reference
SmCB + Montanide ISA 720 VG Reduce parasites 63% Schistosomula Tallima et al26
SmCB + CpG Reduce parasites 53% Schistosomula Tallima et al26
SmCB1 Reduce worms burden 70% Schistosomula Tallima et al26
SjAChE Reduce female worms 30%–44% Eggs and adults You et al28
Reduce fecal eggs 61%–68%
Reduce liver eggs 44%–56%
Reduce intestinal eggs 46%–48%
Reduce mature intestinal eggs 56%–63%
rSjLD1 Reduce male worms 33% Adults You et al29
Reduce liver granuloma density 41%
Reduce mature intestinal eggs 73%

CpG = cytosine-guanine in the linear sequence (CpG or CG oligodeoxynucleotides); rSjLD1 = Schistosoma japonicum insulin receptor 1; SjAChE = Schistosoma japonicum acetylcholinesterace; SmCB + Montonide 720 VG = Schistosoma mansoni chaptesin B + Montanide ISA 720 VG (SEPPIC Inc., Fairfield, NJ, USA); SmCB1 = Schistosoma mansoni chaptesin B1; VG = vegetable-grade.